Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 281

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia

Rosenheck, Robert A., Leslie, Douglas L., Sindelar, Jody, Miller, Edward A., Lin, Haiqun, Stroup, T. Scott, McEvoy, Joseph, Davis, Sonia M., Keefe, Richard S.E., Swartz, Marvin, Perkins, Diana O., Hsiao, John K., Lieberman, Jeffrey · 2006 · American Journal of Psychiatry

Abstract

BACKGROUND: Second-generation antipsychotics have largely replaced first-generation antipsychotics for the treatment of schizophrenia, but a large-scale cost/effectiveness analysis has not been attempted. METHOD: Patients with schizophrenia (N=1,493) were assigned to treatment with a first-generation antipsychotic (perphenazine) or one of four second-generation drugs (olanzapine, quetia-pine, risperidone, or ziprasidone) and followed for up to 18 months. Patients with tardive dyskinesia were prohibited from assignment to perphenazine. Patients could be reassigned at any time to another second-generation drug, including clozapine, but not to perphenazine. The cost analysis included medications plus health services use. Quality-adjusted life year (QALY) ratings were assessed on the basis of Positive and Negative Syndrome Scale (PANSS) subscale scores and side effects. An intention-to-treat analysis included all available observations, classified by initial drug assignment, and costs of reassignment of most patients to another second-generation drug. The analysis was repeated considering only treatment on initially assigned medications. RESULTS: Although QALY ratings, PANSS scores, and other quality of life measures indicated modest improvement over 18 months, there were no significant differences between perphenazine and any second-generation medication. Average total monthly health care costs were 300 dollars-600 dollars (20%-30%) lower for perphenazine than for second-generation antipsychotics because of lower drug cost. Differences in costs remained when maximally discounted drug prices were used for all patients and when only observations during treatment with the first medication were included. CONCLUSIONS: Treatment with perphenazine was less costly than treatment with second-generation antipsychotics with no significant differences in measures of effectiveness. However, the trial was limited by a high dropout rate, and longer-term neurological and metabolic side effects require further study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1176/ajp.2006.163.12.2080

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 10

  1. Revicki DA, 1990, Hosp Community Psychiatry, 41, 850
  2. 10.2165/00019053-199915050-00005 · doi:10.2165/00019053-199915050-00005
  3. Jones PB, Markwick A
  4. First MB, 1995, Williams JBW: Structured Clinical Interview for DSM-IV Axis I and II Disorders, version 2.0
  5. Gold MR, 1996, Russell LB
  6. Drug Topics Red Book, 1999, Medical Economics Company
  7. Thompson Medstat Group, 2002, Marketscan Communical Claims and Encounters Database
  8. 10.1177/0272989X02239649 · doi:10.1177/0272989x02239649
  9. 10.1016/j.schres.2003.11.008 · doi:10.1016/j.schres.2003.11.008
  10. Daniels N, 2003, Sabin J: Setting Limits Fairly: Can We Learn to Share Medical Resources? New York

Cited by

See all 281

Metadata

Authors
Rosenheck, R. A., Leslie, D. L., Sindelar, J., Miller, E. A., Lin, H., Stroup, T. S., McEvoy, J., Davis, S. M., Keefe, R. S. E., Swartz, M., Perkins, D. O., Hsiao, J. K., & Lieberman, J.
Venue
American Journal of Psychiatry
Published
2006-12
Volume
163
Issue
12
Pages
2080-2089
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2133198672
Cited by
281
References
22
FWCI
21.46
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.